Abstract
Serum thyroglobulin (Tg) measurement and whole-body-scintigraphy with 131I (WBS) are widely used for detection of local recurrence, lymph node and distant metastases in the follow-up of differentiated thyroid cancer (1,2). The “myocardial tracers” thallium and 99mTc-MIBI have been proven to be useful besides 131I. 18FDG is known to be retained in malignant tissue, depending on the grade of malignancy. Some reports have been published dealing with FDG uptake in thyroid cancer, partly using a regional-body positron-emission tomography (PET) scanner and partly using a conventional gamma camera (3–6). Recently, Feine et al. (3) published first results obtained with a whole-body PET scanner. The aim of the present study was to evaluate the use of whole-body FDG-PET imaging in the follow-up of patients who have been treated with 131I and to compare the results with other imaging modalities, particularly with MIBI-scintigraphy since this radiopharmaceutical has been proven to be useful in the follow-up of (also 131I-negative) thyroid carcinomas (7).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Goolden AWG. The indication for ablating normal thyroid tissue with 131I in differentiated thyroid cancer. Clin Endocrinol 1985; 23: 81 - 86
Dadparvar S, Krishna L, Brady LW, et al. The role of 1311odine-Na and 201Thallium imaging and serum thyroglobulin in the management of differentiated carcinoma. Cancer 1993; 71: 3767 - 3773
Feine U, Lietzenmayer R, Hanke JP, Wöhrle H, Müller-Schauenburg W. 18FDG whole-body PET in differentiated thyroid carcinoma. Nucl Med 1995; 34: 127 - 134.
Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987; 28: 910 - 914
Sisson JC, Ackermann RJ, Meyer MA. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrin Metabol 1993; 77: 1090 - 1094
Baqai FH, Conti PS, Singer PA, et al. 18F-FDG-PET scanning - a diagnostic tool for detection of recurrent and metastatic differentiated thyroid cancers. Abstract, 68th annual meeting of the American Thyroid Association, Chicago 1994, pp 9
Briele B, Hotze AL, Kropp J, et al. A comparison of 201T1 and 99mTc-MIBI in the follow-up of differentiated thyroid carcinoma. Nucl Med 1991; 30: 115 - 124
Spiessl B, Beahrs OH, Hermanek P, et al. TNM-Atlas. Illustrierter Leitfaden zur TNM/pTNM-Klassifikation maligner Tumoren/International Union Against Cancer/Union Internationale Contre le Cancer (UICC). Springer-Verlag, BerlinHeidelberg-New York, 1993, pp 58
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Basel AG
About this chapter
Cite this chapter
Grünwald, F. et al. (1997). FDG-PET, I-131 and MIBI Scintigraphy in the Follow-Up of Differentiated Thyroid Cancer. In: Bergmann, H., Kroiss, A., Sinzinger, H. (eds) Radioactive Isotopes in Clinical Medicine and Research. Advances in Pharmacological Sciences. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7772-5_9
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7772-5_9
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-7774-9
Online ISBN: 978-3-0348-7772-5
eBook Packages: Springer Book Archive